TrialJournal for immunotherapy of cancer2020
Phase 2 study of pembrolizumab in patients with advanced rare cancers.
Aung Naing et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
95 papers cite itlatest 60 shown
this paperpooled ittrialcites it